secwatch.observer — SEC 8-K summary
======================================

Issuer:     Definium Therapeutics, Inc. (DFTX)
CIK:        0001813814
Form:       8-K
Filed at:   2024-12-16T23:59:59+00:00
Accession:  0000950170-24-136386
Event type: other_material
Sentiment:  neutral
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MindMed doses first patient in Phase 3 Voyage study of MM120 for GAD
--------------------------------------------------------------------

- First-ever Phase 3 study of lysergide D-tartrate (LSD) for GAD; primary endpoint HAM-A change at week 12 vs placebo.
- Voyage study to enroll ~200 participants in US; topline data from 12-week double-blind period expected H1 2026.
- Builds on positive Phase 2b study results presented at APA Annual Meeting in May 2024; second Phase 3 Panorama study on track for H1 2025.
- MM120 ODT is a pharmaceutically optimized form of LSD; study includes 52-week duration with 40-week open-label extension.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1813814/000095017024136386/0000950170-24-136386-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1813814/000095017024136386/mnmd-20241216.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-136386

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer